When.com Web Search

  1. Ads

    related to: companies developing glp 1 drugs
    • Medication Guidelines

      Learn about medication guidelines

      For US Healthcare Professionals.

    • Dosing Data

      Dosing Considerations And Data For

      US Healthcare Professionals.

    • Safety Data

      Safety Info & Side Effects Data For

      US Healthcare Professionals.

    • Clinical Data

      Clinical Trial Data Presented For

      US Healthcare Professionals.

Search results

  1. Results From The WOW.Com Content Network
  2. Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP ...

    www.aol.com/novo-nordisk-eli-lilly-could...

    The Swiss pharma giant is developing multiple GLP-1 weight loss drugs that have been showing promise in early-stage trials. One is CT-388, which is a weekly injectable, similar to the approved GLP ...

  3. New weight loss drugs are coming, and they could burn more ...

    www.aol.com/news/slew-weight-loss-drugs...

    The next wave of obesity drugs is coming soon. Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro ...

  4. These Were the Top-Selling GLP-1 Drugs Last Quarter ... - AOL

    www.aol.com/were-top-selling-glp-1-120000301.html

    Source: Company filings. Currently, Ozempic remains atop the other GLP-1 drugs on this list, but the drug has been available for longer. As the other drugs on this list become more prominent in ...

  5. GLP-1 receptor agonist - Wikipedia

    en.wikipedia.org/wiki/GLP-1_receptor_agonist

    Native GLP-1 is a peptide hormone with a half-life of two minutes because it is rapidly cleared by the enzyme dipeptidyl peptidase-4. [29] As a result, different GLP-1 agonist drugs are modified in various ways to extend the half-life, resulting in drugs that can be dosed multiple times per day, daily, weekly, or less often. [29]

  6. Meet the GLP-1 Drug That Could Be the Biggest Concern ... - AOL

    www.aol.com/finance/meet-glp-1-drug-could...

    MariTide, also known as AMG 133, is a GLP-1 injectable treatment that pharmaceutical company Amgen (NASDAQ: AMGN) has been developing. The results have been incredibly encouraging, as it has been ...

  7. Why Viking Therapeutics Stock Popped, but Novo Nordisk ... - AOL

    www.aol.com/why-viking-therapeutics-stock-popped...

    Conversely, Viking stock may be getting a boost because, although it works much like semaglutide and targets the same hormone semaglutide targets, the GLP-1 drug it is developing (but not yet ...